TY - JOUR T1 - PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC) JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 735 LP - 740 DO - 10.1136/jclinpath-2020-206832 VL - 74 IS - 11 AU - Pedro De Marchi AU - Leticia Ferro Leal AU - Vinicius Duval da Silva AU - Eduardo Caetano Albino da Silva AU - Vladmir Claudio Cordeiro de Lima AU - Rui Manuel Reis Y1 - 2021/11/01 UR - http://jcp.bmj.com/content/74/11/735.abstract N2 - Background For non-small cell lung cancer (NSCLC) the most used method for analysing programmed cell death ligand 1 (PD-L1) expression is the Tumor Proportion Score (TPS). Nevertheless, for other tumour types, the Combined Positive Score (CPS) has been the method of choice.Aim Evaluate and compare the predictive value of both CPS and TPS as predictors of immunotherapy response in NSCLC, and to evaluate the agreement intra-observer between both methods and inter-observer between two expert lung pathologists.Methods 56 NSCLC patients who were treated with anti-programmed cell death 1 (PD-1)/PD-L1 therapy were included. Two pathologists evaluated all cases independently, considering the sample’s adequacy for analysis, and the PD-L1 expression by TPS and CPS.Results The Kappa coefficient for adequacy was 0.82 (95% CI 0.67 to 0.97). There was a high agreement between TPS and CPS and a high agreement between pathologists concerning the two methods. The Kappa coefficient between TPS and CPS was 0.85 for both pathologists, and between pathologists was 0.94 and 0.93 for TPS and CPS, respectively.Conclusions Both methods proved to be equally predictive of response to anti-PD-1/PD-L1 therapy. There was both a high intra-observer agreement between the two methods and a high inter-observer agreement between pathologists. This study suggests that CPS could also be used in a routine setting for immunotherapy decision in NSCLC.All data relevant to the study are included in the article. ER -